Nanoparticles targeting at methylases with high correlation to N^(6)-methyladenosine-related lncRNA signatures as potential therapy of kidney clear cell carcinoma

作     者：Ruixuan Chen Ping Ouyang Licong Su Xi Xu Penghu Lian Yanqin Li Qi Gao Yifan Zhang Sheng Nie Fan Luo Ruqi Xu Xiaodong Zhang Xiaoxi Li Yue Cao Peiyan Gao Juanjuan Kang Jun Wu Lu Li Ruixuan Chen;Ping Ouyang;Licong Su;Xi Xu;Penghu Lian;Yanqin Li;Qi Gao;Yifan Zhang;Sheng Nie;Fan Luo;Ruqi Xu;Xiaodong Zhang;Xiaoxi Li;Yue Cao;Peiyan Gao;Juanjuan Kang;Jun Wu;Lu Li

作者机构：National Clinical Research Center for Kidney DiseaseState Key Laboratory of Organ Failure ResearchGuangdong Provincial Clinical Research Center for Kidney DiseaseNanfang HospitalSouthern Medical UniversityGuangzhou 510000China Department of Health ManagementNanfang HospitalSouthern Medical UniversityGuangzhou 510000China Department of HematologyNanfang HospitalSouthern Medical UniversityGuangzhou 510000China Department of UrologyPeking Union Medical College HospitalChinese Academy of Medical Sciences and Peking Union Medical College(CAMS&PUMC)Beijing 100730China Department of UrologyNanfang HospitalSouthern Medical UniversityGuangzhou 510000China Affiliated Foshan Maternity&Child Healthcare HospitalSouthern Medical UniversityFoshan 528000China School of Biomedical EngineeringSun Yat-sen UniversityShenzhen 518107China Department of Radiation OncologyNanfang HospitalSouthern Medical UniversityGuangzhou 510000China 

出 版 物：《Chinese Chemical Letters》 (中国化学快报（英文版）)

年 卷 期：2022年第33卷第10期

页      面：4610-4616页

核心收录：

学科分类：1002[医学-临床医学] 07[理学] 070205[理学-凝聚态物理] 08[工学] 080501[工学-材料物理与化学] 0805[工学-材料科学与工程（可授工学、理学学位）] 100214[医学-肿瘤学] 0702[理学-物理学] 10[医学] 

基　　金：funded by the National Natural Science Foundation of China(Nos.8210102561,81900626,51973243,52173150) Nanfang Hospital(No.2019C028) International Cooperation and Exchange of the National Natural Science Foundation of China(No.51820105004) Science and Technology Planning Project of Shenzhen(No.JCYJ20190807155801657) Guangdong Innovative and Entrepreneurial Research Team Program(No.2016ZTO6S029) 

主　　题：Nanoparticle Methylation Long noncoding RNA Clear cell renal carcinoma Immunotherapy 

摘      要：Clear cell renal cell carcinoma(ccRCC)is a heterogeneous malignancy with poor *** of the N^(6) position of adenosine(m^(6)A),the most common epigenetic modification in both messenger RNAs and noncoding RNAs,has been reported to regulate the initiation and progression of ***,whether and how m^(6)A-related long noncoding RNAs(m^(6)ArlncRNAs)signify the progression of ccRCC remain *** found m^(6)ArlncRNAs are effective signatures illustrating immune landscape and risk stratification in *** identified two differently expressed m^(6)ArlncRNAs(DEm^(6)ArlncRNAs),AC008870.2 and EMX2OS,as independent risk factors for overall survival of ccRCC patients,by applying stringent variable selection procedure to data from the Cancer Genome Atlas Kidney Renal Clear Cell Carcinoma *** risk score generated from the DEm^(6)ArlncRNA expression categorizes patients into either high or low-risk groups,between which,enrichment analysis indicated an enrichment in immune-related *** different DEm^(6)ArlncRNA transcription pattern,the two risk groups differ in immune cell population composition and expression levels of therapy targeting *** is satisfactory strategy to delivering therapeutic *** further clinical translation,we designed a novel nanoparticle delivery system packaged STM2457(STM@8P4 NPs),which selectively inhibits AC008870.2-correlated m^(6)A ***@8P4 NPs loaded drug successfully with uniform particle size,long-term stability and high release ***@8P4 NPs can easily enter ccRCC cells and showed a highly efficient ccRCC killing activity in *** results therefore indicate that m^(6)ArlncRNAs expression can depict tumor microenvironment,predict prognosis for ccRCC patient and give hint to therapeutic strategies in ccRCC.